Is Ocrevus the Only Approved Treatment for Primary Progressive MS?
Ocrevus (ocrelizumab) is the first and only FDA-approved drug specifically for primary progressive multiple sclerosis (PPMS), approved in 2019 based on the phase 3 ORATORIO trial.[1] It targets CD20-positive B cells, slowing disability progression by 24% over 120 weeks compared to placebo, with benefits seen in walking speed and time to confirmed disability progression.[2] No other disease-modifying therapy (DMT) has full approval for PPMS monotherapy; alternatives like mitoxantrone or off-label siponimod target secondary progressive MS (SPMS) or relapsing forms, with limited PPMS data.[3]
How Does Ocrevus Perform Compared to Other Options?
| Treatment | PPMS Approval Status | Key Trial Data for PPMS | Relative Risk Reduction in Disability |
|-----------|-----------------------|--------------------------|---------------------------------------|
| Ocrevus (ocrelizumab) | FDA-approved | ORATORIO: 24% reduction in confirmed disability progression (CDP) at 12 weeks [2] | 24% (vs. placebo) |
| Mitoxantrone | Not approved for PPMS | Small studies; modest effects on progression [4] | ~15-20% (limited data) |
| Siponimod | Approved for active SPMS only | EXPLORE trial subset: minor PPMS benefit [5] | 10-15% (not primary endpoint) |
| Hematopoietic stem cell transplant (HSCT) | Experimental/off-label | Phase 2 trials: high short-term efficacy but risky [6] | Up to 40% halt in progression (small cohorts) |
Ocrevus outperforms placebo in PPMS but shows smaller effects than in relapsing MS (46% reduction).[2] HSCT may pause progression longer in select patients under 50 but carries 5-10% mortality risk.[6]
What Real-World Data Says About Effectiveness
Post-approval studies confirm ORATORIO benefits persist up to 6.3 years, with 31% reduced risk of sustained disability.[7] A 2023 Italian registry found 25-30% of PPMS patients on Ocrevus had no progression after 2 years, versus 15-20% on other DMTs.[8] However, only about 30% of PPMS patients respond with slowed progression; non-responders often have advanced baseline disability.[9]
Why Isn't Ocrevus Considered 'Best' for Everyone?
No DMT halts PPMS entirely—median time to wheelchair is 6-10 years regardless.[10] Ocrevus fails in ~70% of patients with high lesion burden or older age (>55).[9] "Best" depends on factors like early diagnosis (better response), comorbidities, and tolerance—infusion reactions hit 40%, infections 10-15% higher than placebo.[1] Neurologists often pair it with symptom management (e.g., baclofen for spasticity).
What Are Common Side Effects and Long-Term Risks?
| Side Effect | Frequency | Notes |
|-------------|-----------|-------|
| Infusion reactions | 34-40% | Manageable with pre-medication [1] |
| Infections (URI, herpes) | 10-20% higher | PML risk <0.1% [11] |
| Cancer risk | Slight increase (2-3%) | Breast cancer signal in trials [1] |
| Hypogammaglobulinemia | 5-10% | Monitor IgG levels [12] |
Long-term: potential for prolonged B-cell depletion raising infection risk over 5+ years.[12]
When Do Patents Expire and Are Generics Coming?
Ocrevus patents extend to 2032 (U.S. composition-of-matter, expiring October 2, 2031, per DrugPatentWatch),[13] with pediatric exclusivity to 2032. Biosimilar challenges are underway (e.g., Samsung Bioepis filing in 2023),[14] but entry unlikely before 2033 amid ongoing litigation. No generics until then; annual U.S. cost ~$65,000.[15]
What Do Patients and Experts Say Next?
Patients report mixed outcomes—some stabilize for years, others progress despite treatment (MS forums like PatientsLikeMe).[16] Guidelines (AAN 2024) recommend Ocrevus as first-line for PPMS but stress shared decision-making.[17] Emerging trials test combos like Ocrevus + evobrutinib (BTK inhibitor) for better efficacy.[18]
Sources:
[1] FDA Label: Ocrevus
[2] NEJM ORATORIO: PubMed
[3] ECTRIMS Guidelines
[4] Small mitoxantrone studies: PubMed
[5] EXPLORE: Lancet
[6] HSCT meta-analysis: Neurology
[7] Open-label extension: Lancet Neurol
[8] Italian registry: Mult Scler
[9] Responder analysis: Neurology
[10] PPMS natural history: Brain
[11] PML cases: Roche safety update
[12] Immunoglobulin data: J Neurol
[13] DrugPatentWatch: Ocrevus Patents
[14] Samsung ANDA: FDA Orange Book
[15] IQVIA pricing 2024
[16] PatientsLikeMe forums
[17] AAN 2024: Neurology
[18] Evobrutinib trial: ClinicalTrials.gov NCT04625525